In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Immune Pharmaceuticals Ltd.

Division of Immune Pharmaceuticals Inc.
www.immunepharmaceuticals.com

Latest From Immune Pharmaceuticals Ltd.

Immune/EpiCept Merge To Form Multi-Project Antibody Drug Company

Israeli antibody drug developer Immune Pharmaceuticals will have several projects in the pipeline, including some potential out-licensing candidates, after it makes the leap to a U.S. public company through a reverse-merger with troubled EpiCept, CEO Daniel Teper said during an interview at BIO CEO.

BioPharmaceutical Deals

Deals Shaping The Medical Industry, December 2012

Derived from Strategic Transactions, EBI’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment –In Vitro Diagnostics, Medical Devices, and Pharmaceuticals– and then categorized by type –Acquisition, Alliance, or Financing.

BioPharmaceutical Medical Device

Deals Shaping the Medical Industry (02/2011)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions.
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Middle East
      • Israel
  • Parent & Subsidiaries
  • Immune Pharmaceuticals Inc.
  • Senior Management
  • Daniel Teper, Chmn. & CEO
    Serge Goldner, CFO
    Jean Elie Kadouche, PhD, VP, Innovation & Research
    Suzy Jones, Chief Bus. Dev. Officer
  • Contact Info
  • Immune Pharmaceuticals Ltd.
    Phone: 9 886 6612
    15 Aba Even Ave.
    2nd Fl.
    Herzliya-Pituach, 46733
    Israel
Advertisement
Advertisement
UsernamePublicRestriction

Register